Holen Sie sich die Stockscreener-App
0.3677
0.99%
0.0036
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Will BioAtla Inc. see short term momentumStock Surge & Safe Swing Trade Setups - Newser
Can BioAtla Inc. rally from current levelsEarnings Summary Report & Accurate Entry/Exit Alerts - Newser
How to forecast BioAtla Inc. trends using time seriesEntry Point & Community Trade Idea Sharing Platform - Newser
What analysts say about BioAtla Inc. stock outlookJuly 2025 Outlook & High Accuracy Trade Alerts - Newser
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges - MSN
BioAtla Inc. Testing Reversal Zone on Weekly Chart2025 Top Decliners & Free Long-Term Investment Growth Plans - classian.co.kr
Is BioAtla Inc. stock bottoming outQuarterly Profit Summary & Fast Momentum Entry Tips - Newser
Using data filters to optimize entry into BioAtla Inc.2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Has BioAtla Inc. formed a bullish divergenceTrade Entry Summary & Free Daily Entry Point Trade Alerts - Newser
Combining price and volume data for BioAtla Inc.Stop Loss & High Accuracy Swing Entry Alerts - Newser
What technical models suggest about BioAtla Inc.’s comebackJuly 2025 Rallies & Verified Entry Point Detection - Newser
Exit strategy if you’re trapped in BioAtla Inc.Quarterly Trade Summary & Risk Managed Investment Signals - Newser
BioAtla downgraded to Market Perform from Outperform at Citizens JMP - MSN
JMP Securities Reiterates “Market Perform” Rating for BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Rating Lowered to Market Perform at Citizens Jmp - Defense World
How sentiment analysis helps forecast BioAtla Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - Newser
BioAtla's BCAB Downgraded to Market Perform by JMP Securities - AInvest
HC Wainwright Predicts BioAtla’s Q3 Earnings (NASDAQ:BCAB) - Defense World
BioAtla’s SWOT analysis: oncology biotech’s stock faces cash crunch - Investing.com
BioAtla stock downgraded by Citizens JMP on cash concerns - Investing.com Canada
Will BioAtla Inc. see short term momentum [2025 Market Trends]Accurate Intraday Trading Signals - Newser
Why BioAtla Inc. stock attracts strong analyst attentionDay Trading Plan with Entry Risk Management - Newser
Analysts Apply Wyckoff Model to BioAtla Inc. StockBuy Low Sell High Stock Watch Strategy in Focus - 선데이타임즈
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript - Insider Monkey
What makes BioAtla Inc. stock price move sharplyWatchlist Generator for Smart Money Signals - Newser
BioAtla Inc. stock trend outlook and recovery pathFree Stable Entry High Return Opportunities - Newser
Buy Signal for BioAtla Inc. Stock Key Technical Indicators to WatchFree Conservative Entry for High Return Setup - Newser
What institutional flow reveals about BioAtla Inc.Automated AI Forecast with Trading Alerts - Newser
Can BioAtla Inc. Outperform Peers After Recent PullbackFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Does BioAtla Inc. stock have upside surprise potentialDaily Breakout Recap Watch - sisaissue.com
BioAtla, Inc. Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Head-To-Head Review: Alzamend Neuro (NASDAQ:ALZN) & BioAtla (NASDAQ:BCAB) - Defense World
Sector ETF performance correlation with BioAtla Inc.Free Alpha Driven Watchlist With Alerts - Newser
Comparing BioAtla Inc. in custom built stock radarsFree Swing Setup With Technical Confirmation - Newser
BioAtla's Strategic Position in Immuno-Oncology and Partnership-Driven Growth - AInvest
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):